Abby R Rosenberg1, Joyce P Yi-Frazier2, Lauren Eaton2, Claire Wharton2, Katherine Cochrane2, Catherine Pihoker2, K Scott Baker3, Elizabeth McCauley2. 1. Seattle Children's Research Institute, University of Washington School of Medicine and Fred Hutchinson Cancer Research Center abby.rosenberg@seattlechildrens.org. 2. Seattle Children's Research Institute, University of Washington School of Medicine and. 3. Seattle Children's Research Institute, University of Washington School of Medicine and Fred Hutchinson Cancer Research Center.
Abstract
OBJECTIVE: To examine the feasibility and format of the Promoting Resilience in Stress Management (PRISM) intervention among two groups of adolescents and young adults (AYAs) at-risk for poor outcomes: those with Type 1 diabetes (T1D) or cancer. METHODS: PRISM consists of two long or four short skills-based modules. English-speaking patients 12-25 years old were eligible if they had T1D for >6 months or cancer for >2 weeks. Feasibility was defined as an 80% completion rate and high satisfaction. Ongoing monitoring shaped iterative refinement of disease-specific approach. RESULTS: 12 of 15 patients with T1D (80%) completed the two-session intervention. 3 of 15 patients with cancer declined to complete the two-session version, citing prohibitive length of individual sessions. 12 (80%) completed the four-session version. Patient-reported satisfaction was high across groups. CONCLUSIONS: The PRISM intervention is feasible and well-accepted by AYAs with cancer or T1D. Differences in patient populations warrant differences in approach.
OBJECTIVE: To examine the feasibility and format of the Promoting Resilience in Stress Management (PRISM) intervention among two groups of adolescents and young adults (AYAs) at-risk for poor outcomes: those with Type 1 diabetes (T1D) or cancer. METHODS:PRISM consists of two long or four short skills-based modules. English-speaking patients 12-25 years old were eligible if they had T1D for >6 months or cancer for >2 weeks. Feasibility was defined as an 80% completion rate and high satisfaction. Ongoing monitoring shaped iterative refinement of disease-specific approach. RESULTS: 12 of 15 patients with T1D (80%) completed the two-session intervention. 3 of 15 patients with cancer declined to complete the two-session version, citing prohibitive length of individual sessions. 12 (80%) completed the four-session version. Patient-reported satisfaction was high across groups. CONCLUSIONS: The PRISM intervention is feasible and well-accepted by AYAs with cancer or T1D. Differences in patient populations warrant differences in approach.
Authors: Tonja R Nansel; Barbara J Anderson; Lori M B Laffel; Bruce G Simons-Morton; Jill Weissberg-Benchell; Tim Wysocki; Ronald J Iannotti; Grayson N Holmbeck; Korey K Hood; Amanda S Lochrie Journal: Pediatr Diabetes Date: 2008-08-20 Impact factor: 4.866
Authors: Jane E Gillham; Karen J Reivich; Derek R Freres; Tara M Chaplin; Andrew J Shatté; Barbra Samuels; Andrea G L Elkon; Samantha Litzinger; Marisa Lascher; Robert Gallop; Martin E P Seligman Journal: J Consult Clin Psychol Date: 2007-02
Authors: Paul C Nathan; Mark L Greenberg; Kirsten K Ness; Melissa M Hudson; Ann C Mertens; Martin C Mahoney; James G Gurney; Sarah S Donaldson; Wendy M Leisenring; Leslie L Robison; Kevin C Oeffinger Journal: J Clin Oncol Date: 2008-09-20 Impact factor: 50.717
Authors: Christina N Massey; Emily H Feig; Laura Duque-Serrano; Deborah Wexler; Judith Tedlie Moskowitz; Jeff C Huffman Journal: Diabetes Res Clin Pract Date: 2018-11-27 Impact factor: 5.602
Authors: Marisa E Hilliard; Viena T Cao; Sahar S Eshtehardi; Charles G Minard; Rana Saber; Debbe Thompson; Lefkothea P Karaviti; Barbara J Anderson Journal: Diabetes Technol Ther Date: 2020-05-22 Impact factor: 6.118
Authors: Nancy Lau; Miranda C Bradford; Angela Steineck; Courtney C Junkins; Joyce P Yi-Frazier; Elizabeth McCauley; Abby R Rosenberg Journal: Psychooncology Date: 2019-05-14 Impact factor: 3.894
Authors: Kaitlyn M Fladeboe; Samantha Scott; Miranda C Bradford; Tyler G Ketterl; Joyce P Yi-Frazier; Abby R Rosenberg Journal: J Adolesc Young Adult Oncol Date: 2020-04-21 Impact factor: 2.223
Authors: Abby R Rosenberg; Miranda C Bradford; Krysta S Barton; Nicole Etsekson; Elizabeth McCauley; J Randall Curtis; Joanne Wolfe; K Scott Baker; Joyce P Yi-Frazier Journal: Pediatr Blood Cancer Date: 2018-09-30 Impact factor: 3.167
Authors: Abby R Rosenberg; Karen L Syrjala; Paul J Martin; Mary E Flowers; Paul A Carpenter; Rachel B Salit; K Scott Baker; Stephanie J Lee Journal: Cancer Date: 2015-08-19 Impact factor: 6.860